ORLANDO, Fla., July 31, 2007 (PRIME NEWSWIRE) -- RedChip Visibility, a division of RedChip Companies, Inc., announced that it has issued an initial research report on China Aoxing Pharmaceutical Co. (OTCBB:CAXG).
China Aoxing engages in the manufacture and distribution of analgesic drugs in the People's Republic of China. The Company, founded in 2002 and headquartered in Shijiazhuang City (China's "pharma capital"), is one of a select few firms to be granted permission by China's SFDA (State Food and Drug Administration) to produce a number of leading generic analgesics, in some cases exclusively.
Commenting on China Aoxing, Nancy Hull, Vice President and Director of Equity Research at RedChip Companies, stated, "China Aoxing holds a strong strategic position as one of the first non-government entities to enter China's largely untapped prescription analgesic market. We expect CAXG to deliver significant revenue growth over the next six quarters with sales climbing from $350,000 in CY 2006 to $6.3 million in CY 2007 and $24.6 million in CY 2008."
To receive a complimentary copy of the RedChip Visibility initial report for CAXG, please visit: http://www.redchip.com/visibility/about.asp?page=requestCAXG_initial&from=pressCAXG73107
About RedChip Companies, Inc.
RedChip Companies is an international small-cap research and financial public relations firm with offices in Beijing and Orlando and affiliates in New York and San Diego. RedChip delivers measurable results for its clients through its extensive international market expertise as well as its comprehensive platform of products: RedChip Research, Traditional Investor Relations, Digital Investor Relations, Institutional and Retail Conferences held throughout the United States, and RedChip Radio(tm). To learn more about RedChip's products and services please visit:
http://www.redchip.com/visibility/services.asp.
The RedChip Companies Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=2761
Disclosure
The analysts contributing to this report do not hold any shares of CAXG. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. As such, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed herein are subject to change. CAXG paid RedChip Visibility $30,000 for the RedChip Visibility Research Program, which includes this report.